tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Scynexis resumes patient dosing in Phase 3 MARIO study
PremiumThe FlyScynexis resumes patient dosing in Phase 3 MARIO study
2M ago
SCYNEXIS: Buy Rating Affirmed Amid Strategic Advancements and Promising Antifungal Innovations
Premium
Ratings
SCYNEXIS: Buy Rating Affirmed Amid Strategic Advancements and Promising Antifungal Innovations
3M ago
SCYNEXIS Faces Challenges Amidst Antifungal Developments
Premium
Company Announcements
SCYNEXIS Faces Challenges Amidst Antifungal Developments
3M ago
SCYNEXIS Reports 2024 Financial Results and Updates
PremiumCompany AnnouncementsSCYNEXIS Reports 2024 Financial Results and Updates
5M ago
Scynexis initiates dosing in Phase 1 trial of SCY-247
Premium
The Fly
Scynexis initiates dosing in Phase 1 trial of SCY-247
8M ago
Scynexis reports Q3 EPS (6c), consensus (7c)
Premium
The Fly
Scynexis reports Q3 EPS (6c), consensus (7c)
9M ago
Scynexis to receives $10M milestone payment from GSK
PremiumThe FlyScynexis to receives $10M milestone payment from GSK
1y ago
Scynexis price target lowered to $6 from $7 at Guggenheim
Premium
The Fly
Scynexis price target lowered to $6 from $7 at Guggenheim
1y ago
Scynexis reports FY23 EPS $1.39, consensus $1.42
Premium
The Fly
Scynexis reports FY23 EPS $1.39, consensus $1.42
1y ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100